SYSTEMIC SCLEROSIS

This study tests a new treatment using specially engineered immune cells (CAR-T) to target and calm overactive immune cells in people with autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. About 20 adults aged 18 to 70 with active disease will receive either CD…

This early-stage trial tests a new treatment called AZD0120 for people with certain autoimmune diseases like systemic sclerosis, myositis, or hard-to-treat rheumatoid arthritis. AZD0120 uses a patient's own immune cells, which are modified in a lab to target and attack faulty imm…

This study is testing a new treatment using specially engineered immune cells (CAR T cells) from donated cord blood for people with severe lupus, scleroderma, or Sjogren's syndrome that hasn't improved with standard treatments. The main goal is to check if the therapy is safe and…

This study tests whether adding two immune-targeting drugs (belimumab and rituximab) to standard therapy can improve skin hardening in people with early diffuse systemic sclerosis. About 30 adults will receive either the drug combination or placebo, plus their usual medication, f…

This study tests if itacitinib is safe and effective for adults with systemic sclerosis, a disease that causes skin thickening and organ damage. About 74 participants will receive the drug or a placebo for a year, and doctors will measure changes in skin thickness. The goal is to…

This study tests whether injecting donor stem cells into the muscles around finger ulcers can help them heal in people with systemic sclerosis. The trial includes 20 adults with at least one painful, deep ulcer that did not improve with standard therapy. The main goals are to che…

This study tests whether injecting a patient's own cultured stem cells into the base of finger ulcers can help them heal. It includes 32 adults with scleroderma who have at least one painful finger sore that hasn't healed with standard care. Half will get stem cell injections, ha…

This early-phase study tests a new treatment called CC-97540, which uses a person's own immune cells (CAR T cells) to target and calm the overactive immune system in severe autoimmune diseases like lupus, myositis, scleroderma, and rheumatoid arthritis. The goal is to see if it i…

This study tests a stem cell transplant for people aged 8-24 with severe systemic sclerosis (scleroderma) that hasn't improved with standard treatments. The goal is to see if this approach is safer and still controls the disease. Participants receive high-dose therapy to reset th…

This study tests a new treatment using a patient's own immune cells, modified to target and destroy harmful cells in three severe autoimmune conditions: lupus nephritis, systemic sclerosis, and Sjogren's syndrome with pulmonary hypertension. About 45 adults will receive a single …

This early-stage study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and calm overactive immune cells in autoimmune diseases. The trial includes 18 adults with conditions like lupus, systemic sclerosis, multiple sclerosis, and ot…

This early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. ALLO-329 uses specially engineered immune cells from a donor to target and calm overactive immune cells that cause these diseases. The main goal is to check safety and fi…

This early-stage study is testing a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like lupus, scleroderma, and rheumatoid arthritis that haven't responded to standard therapies. The treatment uses specially engineered immune …

This early-stage study tests a new treatment called CTX112 for people with severe autoimmune diseases like lupus, scleroderma, or myositis that haven't improved with standard therapies. CTX112 uses specially engineered immune cells from a donor to target and attack faulty immune …

This study tests a drug called nemolizumab in 162 adults with systemic sclerosis (a disease that causes skin hardening and organ damage). The goal is to see if it safely reduces skin thickness and helps lung function over 52 weeks. Participants receive either the drug or a placeb…

This study tests a new treatment using a patient's own immune cells, modified to target and destroy faulty B cells that drive autoimmune diseases like lupus, scleroderma, and myositis. Up to 24 adults with active disease will receive the therapy after a short chemotherapy course.…

This study tests a new treatment combining specially designed immune cells (AD-PluReceptor NK cells) with a drug called tafasitamab and chemotherapy for people with autoimmune disorders like systemic sclerosis, lupus, and lupus nephritis. The goal is to find a safe dose and see i…

This early-stage study tests a new cell treatment called YTS109 in about 18 adults with autoimmune diseases like lupus that have not responded to standard therapies. Participants receive a single infusion of these specially designed cells. The main goal is to check safety and see…

This study tests a stem cell transplant to 'reset' the immune system in children and young adults (ages 8–25) with life-threatening lupus or scleroderma that hasn't responded to standard treatments. The approach uses high-dose therapy to wipe out faulty immune cells, then infuses…

This study tests whether combining two drugs, nintedanib and tocilizumab, works better than standard treatments for people with systemic sclerosis (scleroderma) who also have lung scarring. About 86 adults will receive either the combination or usual care for 56 weeks. The main g…

This study tests a new treatment called NKX019, made from donor immune cells engineered to target and calm overactive immune cells. It is for people with certain autoimmune diseases like systemic sclerosis, inflammatory myopathies, or vasculitis. The goal is to see if it is safe …

This early-stage trial tests a treatment called CABA-201, made from a patient's own immune cells (CAR T cells), for people with systemic sclerosis (scleroderma). The goal is to see if it is safe and can help control the disease by targeting and reducing certain immune cells. Abou…

This study is building a large database and sample bank from 5,000 adults with various rheumatic diseases like rheumatoid arthritis, lupus, and psoriatic arthritis. Researchers will use this information to find links between patient outcomes and biological markers. The goal is to…

This study follows 500 adults with systemic sclerosis (a rare disease causing skin and organ hardening) for 5 years. Researchers will collect health data and blood samples to track how the disease naturally progresses. The goal is to better understand the disease, not to test a n…

This study aims to better understand systemic sclerosis, a rare disease that causes skin hardening and organ damage. Researchers will analyze skin and blood samples from 40 adults to see how different cells behave. The goal is to find new clues for future treatments, not to test …

This study looks at the gut bacteria of people with systemic sclerosis (a chronic autoimmune disease) and compares them to healthy volunteers. Researchers want to see how the bacteria change over 7 months in patients, while healthy people provide just one sample. The goal is to f…